Research - Page 49 of 720 Posts on Medivizor
Navigation Menu

Research Posts on Medivizor

Which is the best approach for treating lateral lymph node metastasis in locally advanced rectal cancer?

Which is the best approach for treating lateral lymph node metastasis in locally advanced rectal cancer?

Posted by on Sep 17, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the best approach for treating lateral lymph node (LLNs) metastasis in patients with locally advanced rectal cancer (LARC). The data showed that a radiation dose boost is an effective way of increasing the response rate and decreasing recurrence rates in these patients. Some background Rectal cancer (RC) is one...

Read More

Does early use of high-dose glucocorticoids affect survival in patients with advanced melanoma treated with anti-PD-1 therapy?

Does early use of high-dose glucocorticoids affect survival in patients with advanced melanoma treated with anti-PD-1 therapy?

Posted by on Sep 17, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the use of high-dose glucocorticoids (GCs) and their impact on the survival outcomes during anti-PD-1 therapy for the treatment of patients with advanced melanoma. The data showed that early high-dose GC use was associated with poorer outcomes after the onset of immune-related side effects. Some background...

Read More

Real-world clinical outcomes for patients with chronic myeloid leukemia who needed to switch from second generation TKI therapy.

Real-world clinical outcomes for patients with chronic myeloid leukemia who needed to switch from second generation TKI therapy.

Posted by on Sep 16, 2021 in Leukemia | 0 comments

In a nutshell This study described real-world outcomes for patients with chronic myeloid leukemia (CML) that started a second-generation tyrosine kinase inhibitor (TKI) therapy and needed to switch to an alternative TKI. The authors concluded that intolerance was the major reason to switch to an alternative TKI and that outcomes were very good...

Read More

How effective is a netupitant and palonosetron combination in preventing nausea and vomiting in patients with multiple myeloma?

How effective is a netupitant and palonosetron combination in preventing nausea and vomiting in patients with multiple myeloma?

Posted by on Sep 16, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study assessed the effectiveness of netupitant/palonosetron (NEPA; Akynzeo) in preventing nausea and vomiting in patients with multiple myeloma (MM) while receiving high-dose melphalan (HDM; Alkeran) and autologous stem cell transplantation (ASCT). The data showed that NEPA, without dexamethasone (DXM; Decadron), was...

Read More

Do tyrosine kinase inhibitors benefit patients with mutant inoperable NSCLC?

Do tyrosine kinase inhibitors benefit patients with mutant inoperable NSCLC?

Posted by on Sep 16, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated whether patients with unresectable non-small-cell lung cancer (NSCLC) having genetic mutations could benefit from first-line treatment with tyrosine kinase inhibitor (TKI) therapy. The data showed that TKIs could be a good option for these patients. Some background NSCLC is the most common form of lung cancer....

Read More

Effectiveness of VCD-VTD therapy for older patients with newly diagnosed multiple myeloma.

Effectiveness of VCD-VTD therapy for older patients with newly diagnosed multiple myeloma.

Posted by on Sep 12, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study assessed the effects of administering personalized doses of VCD (bortezomib, cyclophosphamide, and dexamethasone) followed by VTD (bortezomib, thalidomide, and dexamethasone) in older patients with newly diagnosed multiple myeloma (NDMM). The data showed high response rates and safety in these patients. Some background...

Read More

Evaluating the best timing of surgery after chemoradiotherapy in patients with locally advanced non-small cell lung cancer.

Evaluating the best timing of surgery after chemoradiotherapy in patients with locally advanced non-small cell lung cancer.

Posted by on Sep 12, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the optimal time interval between chemoradiotherapy (CRT) and surgery and its impact on survival outcomes in patients with locally advanced (LA) non-small-cell lung cancer (NSCLC). The data showed that surgery within 7 weeks after CRT was associated with improved survival outcomes in these patients. Some...

Read More

Comparing platinum-based chemotherapy and immunotherapy for the treatment of patients with early-stage triple negative breast cancer.

Comparing platinum-based chemotherapy and immunotherapy for the treatment of patients with early-stage triple negative breast cancer.

Posted by on Sep 12, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) for the treatment of patients with early-stage triple-negative breast cancer (TNBC). The data showed that ICI plus chemotherapy was associated with good outcomes with reduced side effects compared with...

Read More

Can a dual trigger shot improve IVF birth rates?

Can a dual trigger shot improve IVF birth rates?

Posted by on Sep 12, 2021 in Infertility | 0 comments

In a nutshell This study looked at whether using two hormone injections to trigger ovulation can improve birth rates from assisted reproductive technology (ART) when all embryos are frozen. It found that cycles with trigger injections of both human chorionic gonadotropin (hCG; Pregnyl) and GnRH agonist (Decapeptyl) had higher birth rates. Some...

Read More

Can FDG-PET/CT help predict T-cell therapy outcomes for patients with B-cell NHL?

Can FDG-PET/CT help predict T-cell therapy outcomes for patients with B-cell NHL?

Posted by on Sep 12, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the role of PET/CT scanning in the treatment of patients with recurrent or hard-to-treat B-cell non-Hodgkin’s lymphoma (NHL) after T-cell therapy. This study found that PET/CT scanning helped predict the effectiveness and side effects of treatment for these patients. Some background Chemoimmunotherapy...

Read More

Does high-dose statin treatment before percutaneous coronary intervention improve outcomes in patients with coronary artery disease?

Does high-dose statin treatment before percutaneous coronary intervention improve outcomes in patients with coronary artery disease?

Posted by on Sep 12, 2021 in Coronary artery disease | 0 comments

In a nutshell This study looked at the use of high-dose statin treatment before percutaneous coronary intervention (PCI) in patients with coronary artery disease (CAD). It found that patients who received high-dose statin treatment before PCI were less likely to have a major cardiovascular event (MACE) defined as a heart attack or stroke in the next...

Read More